Dare Bioscience (DARE) Projected to Post Earnings on Thursday

Dare Bioscience (NASDAQ:DARE) is projected to post its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Dare Bioscience to announce earnings of ($0.1267) per share and revenue of $2.04 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:30 PM ET.

Dare Bioscience (NASDAQ:DARE) last released its earnings results on Thursday, August 13th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. Dare Bioscience had a negative net margin of 803.80% and a negative return on equity of 748.30%. The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.00 million. On average, analysts expect Dare Bioscience to post ($0.74) EPS for the current fiscal year and ($0.51) EPS for the next fiscal year.

Dare Bioscience Trading Up 6.4%

Shares of NASDAQ:DARE opened at $0.68 on Tuesday. Dare Bioscience has a one year low of $0.61 and a one year high of $3.78. The company has a 50 day moving average of $0.73 and a 200-day moving average of $1.53.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on DARE. Benchmark restated a “buy” rating on shares of Dare Bioscience in a report on Monday, August 17th. UBS Group set a $1.00 target price on shares of Dare Bioscience in a report on Monday, September 14th. HC Wainwright reaffirmed a “buy” rating on shares of Dare Bioscience in a report on Monday, August 17th. Weiss Ratings cut shares of Dare Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Finally, LADENBURG THALM/SH SH initiated coverage on Dare Bioscience in a research note on Monday, October 26th. They issued a “buy” rating and a $2.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Dare Bioscience Company Profile

Daré Bioscience, Inc (NASDAQ: DARE) is a biopharmaceutical company focused on developing and commercializing therapies designed to address unmet needs in women’s health. The company’s research and development activities span contraception, vaginal health, sexual health and reproductive health, with an emphasis on pharmaceutical products and drug-delivery technologies.

Daré’s lead commercial product is XACIATO (clindamycin phosphate) vaginal gel 2%, an FDA-approved prescription treatment for bacterial vaginosis in females 12 and older.